


# Iceland

## Icelandic Medicine Pricing and Reimbursement Committee (IMPRC)

### High-cost medicines

<p><b>- Policy regarding expensive medicines:</b></p> <p>The Pharmaceutical and Therapeutic Committee of the University Hospital (LSH) assesses and includes new and expensive hospital drugs for in and out patient care paid by the Social Insurance (SI)</p> <p>Before finally deciding to introduce a new and expensive medicine an overall estimate (annual basis) of the budgetary impact and health outcomes is performed</p> <p>High-cost medicines are within the S-group (hospital drugs)</p> <p>No official criteria for 'Expensive' Unofficial list at the University Hospital Pharmaceutical and therapeutic committee(LSH)-application system 100% reimbursement – no copayment Budget at Social Insurance, hospitals and nursing homes</p>	
<p>RESEARCH REPORT ADOPTION OF EXPENSIVE PHARMACEUTICALS, A CASE STUDY IN ICELAND AND THE NETHERLANDS</p> <p>Kathleen Parel</p> <p><b>Ministry of Welfare, Reykjavík University of Iceland, faculty of pharmacy University of Utrecht, department of pharmacy</b></p> <p><b>Objective</b> to explore the adoption of 'expensive' pharmaceuticals in the Netherlands and Iceland and compare the two approaches, aiming at making recommendations to policymakers.</p> <p><b>Conclusions</b> Among the recommendations to policymakers in Iceland is to treat expensive pharmaceuticals as a special group with a specific policy and matching legal basis in order to control costs and make efficient use of these medicines. Clear criteria have to be set in order to obtain a transparent and and workable system.</p>	